NCT05512520View on ClinicalTrials.gov

Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）

PHASE2RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

August 30, 2024

Study Completion Date

September 30, 2025

Conditions
Metastatic Esophageal Squamous Cell Carcinoma
Interventions
COMBINATION_PRODUCT

Intensity-modulated radiotherapy concurrent with capecitabine

All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks.

Trial Locations (1)

510000

RECRUITING

Sun yat-sen University Cancer center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER